BUSINESS
Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
Kyowa Hakko Kirin has initiated a Japan PII clinical study of the NHE3 inhibitor tenapanor (development code: KHK7791) in hyperphosphatemia patients, it said on February 6. The PII study is designed to investigate the efficacy and safety of the compound…
To read the full story
Related Article
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





